A study comparing the treatment benefits of MPDL32018 used alone and used together with Avastin to Sunitinb. Benefit is being studied in patients who have advanced kidney cancer or kidney cancer which has spread to other parts of the body and has not been treated before. Acesta este un studiu de faza II, multicentric, randomizat, cu etichetă vizibilă, conceput pentru a estima eficacitatea MPDL3280A + bevacizumab şi a MPDL3280A monoterapie faţă de sunitinib la pacienţii cu RCC confirmat histologic, inoperabil, avansat local sau metastatic, care nu au beneficiat anterior de terapie sistemică nici în contextul adjuvant, nici în cel metastatic To evaluate the efficacy of MPDL3280A + bevacizumab and MPLD3280A monotherapy compared with sunitinib as measured by progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors, V...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study of MPDL3280A (ANTI PD-L1 ANTIBODY) in Patients with PD-L1-selected, High-risk Muscle-invasive Bladder Cancer after Surgery To evaluate the efficacy of adjuvant MPDL3280A treatment in patients with programmed death ligand 1 (PD L1) selected muscle invasive bladder cancer (MIBC), as measured by disease-free survival (DFS)

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized, phase 3, controlled, double-blind, parallel-group, multicenter study to evaluate the safety and efficacy of rituximab in combination with methotrexate (MTX) compared to MTX alone, in methotrexate-naïve patients with active rheumatoid arthritis 1. To determine the efficacy of rituximab in the prevention of progression in structural joint damage and to evaluate the safety of rituximab in patients with active rheumatoid arthritis initiating tr...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy as Neoadjuvant Therapy in Patients With HER2-Positive Early Breast Cancer The primary objective of this study is to evaluate the cardiac safety of neoadjuvant treatment with the following regimens: • ddAC-->T+ PH: Dose-dense doxorubicin and cyclophosphamide (ddAC) given ev...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An open-label, randomized 2-period crossover study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability of warfarin in combination with oseltamivir in volunteers stabilized on warfarin therapy • To investigate the effect of a 5-day treatment course with oseltamivir on the pharmacodynamics of warfarin in volunteers stabilized on warfarin

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study of a combination of Trastuzumab and Capecitabine with or without Pertuzumab in patients with HER2-positive metastatic breast cancer Studie porovnávající kombinaci Trastuzumabu a Capecitabinu podávanou s nebo bez Pertuzumabu u pacientek s HER2 pozitivním metastatickým karcinomem prsu To compare progression-free survival (PFS) between the two treatment arms based on assessments by an independent review facility (IRF).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Open-label study of bevacizumab (Avastin®) plus taxane monotherapy or in combination for the first-line treatment of patients with locally recurrent or metastatic breast cancer The primary objective is to assess the safety profile of bevacizumab when combined with taxane monotherapy or in combination as first line treatment of patients with locally recurrent (LR) or metastat...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study of Pirfenidone in Patients with Unclassifiable Progressive Fibrosing Interstitial Lung Disease •To evaluate the effect of pirfenidone versus (vs.) placebo on lung function parameters

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer’s Disease Estudio de Eficacia y Seguridad de Crenezumab en pacientes con Enfermedad de Alzheimer de Prodromica a leve To evaluate the efficacy of crenezumab compared with placebo based on change from baseline to Week (W) 105 in global outcomes as assessed by Clinical Dementia Rating-Sum of Boxes (CDR-SB) Evalua...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Estudio abierto, aleatorizado, controlado y de grupos paralelos para evaluar la eficacia, seguridad y tolerabilidad de MIRCERA por vía subcutánea frente a la ausencia de tratamiento con ESA, en el tratamiento de la anemia en pacientes con nefropatía crónica después del trasplante renal. A controlled open label randomised parallel group study to evaluate the efficacy, safety, and tolerability of subcutaneous MIRCERA, versus no ESA therapy, in the treatment of anaemia in CKD patients after kidney transplant To assess the efficacy of subcutaneous administration of MIRCERA every two weeks, versus no ESA therapy, in CKD patients with anaemia after kidney transplant not currently treated with ESA.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune